Latest News

AE checklists, lipid monitoring, cognitive screening and symptom tracking. Practical tools that make follow-up systematic rather than reactive.

The question is not whether the patient has progressed, but where and how. Interpreting isolated CNS, oligoprogressive and widespread systemic progression.

Start at 100 mg, interrupt early, reduce strategically. Dose reduction in early weeks did not compromise PFS or intracranial outcomes.

Hypercholesterolemia occurs in 70–75% of patients on lorlatinib, with median onset around 15 days. Monitoring schedules and preferred statins by interaction profile.

In ALK+ NSCLC the brain is often involved at diagnosis, not late. Why CNS efficacy must be a primary treatment selection criterion, and what to monitor.

CNS effects on lorlatinib are usually early, Grade 1–2, and reversible. The real risk is delayed recognition. How to interrupt rapidly and re-initiate safely.

Neuropathy on lorlatinib often begins subtly and can persist if ignored. How to recognise the pattern, assess functional impact, and keep patients on therapy safely.

Peripheral edema is common on lorlatinib. How to distinguish benign swelling from functionally limiting cases, and manage it stepwise without interrupting therapy.

Weight gain occurred in approximately 44% of patients on lorlatinib in long-term CROWN follow-up. How to recognise the pattern early and counsel patients realistically.

Prepare, Monitor, Manage, Reassess: a practical framework for keeping patients with ALK-positive NSCLC on lorlatinib. Presented by Dr. Geoffrey Liu.